glp 1/gip receptor agonist GLP1-GIP co-agonists: a promising evolution in the treatment of type 2 diabetes | Acta Diabetologica Beyond GLP1: modulating multiple nutrient-stimulated

The absence of evidence of harm is not evidence of safety

These aren't symptoms that should be downplayed

Risk of bias assessment was completed for the four randomized controlled trials examining GFCF dietary interventions (Fig

Cardiovascular effects beyond cardiac hypertrophy are poorly characterized for IGF-1 DES specifically, though IGF-1 influences cardiovascular physiology through effects on vascular smooth muscle, endothelial function, blood pressure regulation, and cardiac contractility - chronic perturbation of these processes carries unknown risks

The major costs of ATP during the skeletal muscle contraction are via myosin ATPase and SERCA (88)